Shares in Grifols jumped sharply on Wednesday morning after news website El Confidencial reported that Canadian fund ...

Brookfield Asset Management Ltd. has revived talks with Grifols SA’s main shareholder about a potential offer for the Spanish ...

Brookfield Asset Management Ltd. has resumed contacts with Spanish blood-plasma company Grifols SA on a possible offer that could be worth €7 billion ($7.6 billion) following a failed earlier attempt, ...

The takeover deliberations come shortly after Grifols completed the sale of its 20% stake in Chinese blood products unit Shanghai RAAS to Haier, a deal first announced in 2020, raising cash of ...

First formed in 1909 and headquartered in Barcelona, Grifols is a manufacturer of plasma-based pharmaceuticals and other products like blood transfusion diagnostics, which is tax-domiciled in ...

Grifols, S.A. (NASDAQ:GRFS) is a Spanish global healthcare company specializing in plasma-derived therapies, diagnostics, and hospital pharmacy products. The company was founded in 1909 in ...

Grifols SA engages in the production of plasma ... The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment ...

Learn more about whether Alvotech or Grifols, S.A. is a better investment based on AAII's A+ Investor grades, which compare ...

Grifols (GRFS) issued a statement to address certain information published in a media outlet on March 8, specifically a front-page article titled “The CNMV reveals to the judge ‘continuous ...

Additionally, they noted a decrease in competitive risks for Grifols (BME:GRLS)' immunoglobulin products. Grifols, a global healthcare company, has been working on enhancing its operational ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.